BR112012007114A2 - métodos e composições para tratamento da fibrose ocular - Google Patents
métodos e composições para tratamento da fibrose ocularInfo
- Publication number
- BR112012007114A2 BR112012007114A2 BR112012007114A BR112012007114A BR112012007114A2 BR 112012007114 A2 BR112012007114 A2 BR 112012007114A2 BR 112012007114 A BR112012007114 A BR 112012007114A BR 112012007114 A BR112012007114 A BR 112012007114A BR 112012007114 A2 BR112012007114 A2 BR 112012007114A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- compositions
- ocular fibrosis
- treating ocular
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
Abstract
métodos e composições para tratamento da fibrose ocular. a presente invenção refere-se a métodos e composições para o tratamento da fibrose ocular, como ocorre, por exemplo, durante o tratamento de glaucoma por trabeculotomia. composições compreendem moduladores da atividade de uma ou mais enzimas do tipo lisil oxidase (por exemplo, lox, loxl2), e os métodos incluem métodos para preparar os moduladores, e métodos para administração dos moduladores para um indivíduo com necessidade dos mesmos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27791809P | 2009-09-29 | 2009-09-29 | |
US39745610P | 2010-06-11 | 2010-06-11 | |
PCT/US2010/050542 WO2011041309A1 (en) | 2009-09-29 | 2010-09-28 | Methods and compositions for treatment of ocular fibrosis |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012007114A2 true BR112012007114A2 (pt) | 2016-07-05 |
Family
ID=43780639
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012007114A BR112012007114A2 (pt) | 2009-09-29 | 2010-09-28 | métodos e composições para tratamento da fibrose ocular |
Country Status (11)
Country | Link |
---|---|
US (1) | US20110076285A1 (pt) |
EP (1) | EP2482814A4 (pt) |
JP (1) | JP2013506005A (pt) |
KR (1) | KR20120091146A (pt) |
CN (1) | CN102711753A (pt) |
AU (1) | AU2010300813A1 (pt) |
BR (1) | BR112012007114A2 (pt) |
CA (1) | CA2775877A1 (pt) |
MX (1) | MX2012003759A (pt) |
RU (1) | RU2012117896A (pt) |
WO (1) | WO2011041309A1 (pt) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
US8461303B2 (en) | 2007-08-02 | 2013-06-11 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
WO2010091279A1 (en) * | 2009-02-06 | 2010-08-12 | Arresto Biosciences, Inc. | Methods and compositions for treatment of neovascularization |
WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
US20110044981A1 (en) * | 2009-08-21 | 2011-02-24 | Spangler Rhyannon | Methods and compositions for treatment of pulmonary fibrotic disorders |
MX2012002271A (es) * | 2009-08-21 | 2012-07-20 | Gilead Biologics Inc | Metodos y composiciones terapeuticas. |
RU2012110585A (ru) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
CN105622757A (zh) * | 2010-02-04 | 2016-06-01 | 吉联亚生物科技有限公司 | 结合赖氨酰氧化酶样2(loxl2)的抗体和其使用方法 |
KR20180119654A (ko) | 2016-03-08 | 2018-11-02 | 더 유니버시티 오브 유타 리서치 파운데이션 | 가교-결합제 및 관련 방법 |
EP3500278A4 (en) | 2016-08-19 | 2020-04-01 | Calimmune, Inc. | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CONDITIONS USING A RECOMBINANT SELF-COMPLEMENTARY ADENO-ASSOCIATED VIRUS |
US20200318080A1 (en) * | 2016-08-19 | 2020-10-08 | Colorado State University Research Foundation | Methods and compositions for treating equine conditions using recombinant self-complementary adeno-associated virus |
US11958886B2 (en) | 2016-12-07 | 2024-04-16 | University Of Florida Research Foundation, Incorporated | IL-1RA cDNAs |
US20210002641A1 (en) * | 2018-03-16 | 2021-01-07 | The Regents Of The University Of Michigan | Compositions and methods for treating graves disease |
GB201809295D0 (en) | 2018-06-06 | 2018-07-25 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
KR20200030875A (ko) | 2018-09-13 | 2020-03-23 | 전남대학교산학협력단 | 트리코스타틴 a를 유효성분으로 포함하는 결막 섬유화 억제용 약학적 조성물 |
GB201818750D0 (en) | 2018-11-16 | 2019-01-02 | Institute Of Cancer Res Royal Cancer Hospital | Lox inhibitors |
GB202209622D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Compounds |
GB202209624D0 (en) | 2022-06-30 | 2022-08-17 | Institute Of Cancer Res Royal Cancer Hospital | Prodrugs |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6300092B1 (en) * | 1999-01-27 | 2001-10-09 | Millennium Pharmaceuticals Inc. | Methods of use of a novel lysyl oxidase-related protein |
US20030152926A1 (en) * | 1999-08-11 | 2003-08-14 | Eos Biotechnology, Inc. | Novel methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators |
US20030114410A1 (en) * | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
WO2006068829A1 (en) * | 2004-12-21 | 2006-06-29 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of lysyl oxidase (lox) and lox-like proteases as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
US20070021365A1 (en) * | 2005-06-21 | 2007-01-25 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of Lysyl oxidase for treating tumor growth and diagnostics relating thereto |
US20070225242A1 (en) * | 2005-06-21 | 2007-09-27 | The Board Of Trustees Of The Leland Stanford Junior University | Method and composition for treating and preventing tumor metastasis in vivo |
IL184627A0 (en) * | 2007-07-15 | 2008-12-29 | Technion Res & Dev Foundation | Agents for diagnosing and modulating metastasis and fibrosis as well as inflammation in a mammalian tissue |
US8461303B2 (en) * | 2007-08-02 | 2013-06-11 | Gilead Biologics, Inc. | LOX and LOXL2 inhibitors and uses thereof |
US8815946B2 (en) * | 2008-01-25 | 2014-08-26 | University of Pittsburgh—of the Commonwealth System of Higher Education | Inhibition of proliferation and fibrotic response of activated corneal stromal cells |
WO2010080769A2 (en) * | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
WO2010091279A1 (en) * | 2009-02-06 | 2010-08-12 | Arresto Biosciences, Inc. | Methods and compositions for treatment of neovascularization |
US20110044981A1 (en) * | 2009-08-21 | 2011-02-24 | Spangler Rhyannon | Methods and compositions for treatment of pulmonary fibrotic disorders |
MX2012002271A (es) * | 2009-08-21 | 2012-07-20 | Gilead Biologics Inc | Metodos y composiciones terapeuticas. |
WO2011022670A1 (en) * | 2009-08-21 | 2011-02-24 | Arresto Biosciences, Inc | In vivo screening assays |
RU2012110585A (ru) * | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
-
2010
- 2010-09-28 CN CN2010800538989A patent/CN102711753A/zh active Pending
- 2010-09-28 KR KR1020127010920A patent/KR20120091146A/ko not_active Application Discontinuation
- 2010-09-28 US US12/892,574 patent/US20110076285A1/en not_active Abandoned
- 2010-09-28 RU RU2012117896/15A patent/RU2012117896A/ru not_active Application Discontinuation
- 2010-09-28 WO PCT/US2010/050542 patent/WO2011041309A1/en active Application Filing
- 2010-09-28 JP JP2012532238A patent/JP2013506005A/ja not_active Withdrawn
- 2010-09-28 BR BR112012007114A patent/BR112012007114A2/pt not_active IP Right Cessation
- 2010-09-28 CA CA2775877A patent/CA2775877A1/en not_active Abandoned
- 2010-09-28 MX MX2012003759A patent/MX2012003759A/es not_active Application Discontinuation
- 2010-09-28 EP EP10821110A patent/EP2482814A4/en not_active Withdrawn
- 2010-09-28 AU AU2010300813A patent/AU2010300813A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2013506005A (ja) | 2013-02-21 |
CA2775877A1 (en) | 2011-04-07 |
WO2011041309A1 (en) | 2011-04-07 |
EP2482814A4 (en) | 2013-04-03 |
EP2482814A1 (en) | 2012-08-08 |
KR20120091146A (ko) | 2012-08-17 |
AU2010300813A1 (en) | 2012-04-26 |
US20110076285A1 (en) | 2011-03-31 |
RU2012117896A (ru) | 2013-11-10 |
CN102711753A (zh) | 2012-10-03 |
MX2012003759A (es) | 2012-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112012007114A2 (pt) | métodos e composições para tratamento da fibrose ocular | |
HN2010002774A (es) | DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA | |
BRPI0808775A2 (pt) | compostos e composições como moduladores de atividade de gpr119 | |
CY1118984T1 (el) | Παρασκευη ενεργων, ακρως φωσφορυλιωμενων, ανθρωπινων λυσοσωμικων ενζυμων σουλφατασης και χρησεις αυτων | |
BRPI1011710B8 (pt) | composição para ser usada como uma lágrima artificial | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
BRPI1007379B8 (pt) | composições farmacêuticas para o tratamento ou prevenção de infecções orais por e. coli | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BR112013028907A2 (pt) | conjugados de proteína-agente ativo e método para preparar os mesmos | |
BR112012008004A2 (pt) | compostos e composições como moduladores da atividade de gpr119 | |
EA201001329A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
BRPI0919447B8 (pt) | compostos derivados de ácido 1-amino-2- ciclobutiletilborônico, composição farmacêutica e uso dos mesmos para tratar câncer | |
BR112012004696A2 (pt) | compostos e composições como moduladores da atividade de tlr | |
EP2494059A4 (en) | USE OF METHYSULFONYLMETHANE (MSM) FOR MODULATION OF MICROBIAL ACTIVITY | |
EA201100138A1 (ru) | 4-феноксиметилпиперидины в качестве модуляторов активности gpr119 | |
EA201001332A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MX2011008296A (es) | Metodos y composiciones para el tratamiento de neovascularizacion. | |
EA201001330A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
DE602008005173D1 (de) | Ophthalmische zusammensetzungen auf basis von tamarinden-samen-polysacchariden und hyaluronsäure | |
MX2016001006A (es) | Policonjugados para suministro de desencadenantes de acido ribonucleico de interferencia (arni) en celulas tumorales en vivo. | |
BR112014010376A2 (pt) | medicamento para o tratamento de doença do olho anterior que compreende rebamipida e um agente de retenção de lágrima | |
BR112012015202A2 (pt) | "iota - e/ou kappa-carrgenado junto com um inibidor da neuraminidase, método para o tratamento profilático ou terapêutico de um sintoma, condição ou doença, composição farmacêutica,e, kit de partes". | |
UY32896A (es) | Composiciones de enzimas pancreáticas y métodos para tratar pancreatitis e insuficiencia pancreática | |
BRPI0517551A (pt) | análogos de poliamina como agentes terapêuticos para doenças oculares | |
BR112012022074A2 (pt) | composição compreendendo como ingredientes ativos l-carnitina em combinação com hidroxiquinurenina-o-beta-dl-glicosídeo, para a prevenção e/ou tratamento de patologias dos olhos devido à radiação ultravioleta |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A, 5A E 6A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
B350 | Update of information on the portal [chapter 15.35 patent gazette] |